Also Read: Lupin launches generic ophthalmic solution in US market
Gupta further adds that Lupin, at the moment, will not apply for the different strengths of the capsule as there is a possibility of confusion in the market. The company's main intention now would be to build the product sensibly so that physicians are able to recall and patients can identify the product and the brand.
Below is the verbatim transcript of Nilesh Gupta's interview on CNBC-TV18
Q: How much of an incremental increase could you see in sales or maybe strengthening of market share because of the approvals that you have received on Antara?
A: Antara has been a bit of a roller coaster in the past few months. We had generic competition coming in on the brand itself and while we have retained somewhere between two-thirds and three-fourth of prescriptions between our own brand and the authorised generic, the pricing has been down and there is a competitor on the market and others will follow. This was something which was brewing for a while.
The first goal with the new formulation and the new strengths will be to take back some share or a large part of the market that we have lost and build back the brand. The market that this product competes in has been moving to lower and lower strengths and this is the lowest strength that is available now in the market and it will be a nice positioning for the product. So, it will help our brand business to build back whatever we have lost.
Q: Are you applying for different strengths of this capsule?
A: No, not right now. It is important not to create confusion in the market. We have promoted the whole product for four years and also the intention would be to build it sensibly so that physicians are able to recall the product, patient identify with the product and the brand as well; therefore, you need to go systematically.
I do not think you can go left, right and center doing newer strengths or newer formulations. This was just a value add and that is why it was done for this product. It was brewing for a while and we are just happy to get the approval at this time.
Q: You clocked around half a million dollars in terms of sales for Antara, what do you expect to generate considering that there is now competition which has come through?
A: I am not sure if you got the number right. The brand ran somewhere in the USD 50-70 million kind of range last year before generics came in. Right now, the market has been clearing through inventory, so even the numbers of the last quarter will not give a good idea. What we are talking about building back is building back the brand.
On October 22, 2013, Lupin closed at Rs 916.70, up Rs 3.25, or 0.36 percent. The 52-week high of the share was Rs 946.35 and the 52-week low was Rs 557.10.
The company's trailing 12-month (TTM) EPS was at Rs 29.32 per share as per the quarter ended June 2013. The stock's price-to-earnings (P/E) ratio was 31.27. The latest book value of the company is Rs 108.18 per share. At current value, the price-to-book value of the company was 8.47.
Anda sedang membaca artikel tentang
Lupin to rely on Antara sales to rebuild brand: MD
Dengan url
http://kebugaranhidup.blogspot.com/2013/10/lupin-to-rely-on-antara-sales-to.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Lupin to rely on Antara sales to rebuild brand: MD
namun jangan lupa untuk meletakkan link
Lupin to rely on Antara sales to rebuild brand: MD
sebagai sumbernya
0 komentar:
Posting Komentar